Stock SAVA CASSAVA SCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Cassava Sciences, Inc.

Equities

SAVA

US14817C1071

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-22 pm EDT 		5-day change 1st Jan Change
22.12 USD -0.67% Intraday chart for Cassava Sciences, Inc. -3.87% -1.73%
May. 17 HC Wainwright Adjusts Price Target on Cassava Sciences to $131 From $124, Maintains Buy Rating MT
May. 10 Cassava Sciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
HC Wainwright Adjusts Price Target on Cassava Sciences to $131 From $124, Maintains Buy Rating
MT
Cassava Sciences Reports Q1 2024 Financial Results and Clinical Updates on Phase 3 Trials of Simufilam
AQ
Cassava Sciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Cassava Sciences Reports Q1 2024 Financial Results and Clinical Updates on Phase 3 Trials of Simufilam
GL
Cassava Sciences Raises More Than $125 Million From Warrant Distribution
MT
Cassava Sciences Announces Over $125 Million Raised from Warrant Distribution
GL
North American Morning Briefing : Stock Futures -2-
DJ
Cassava Sciences : Warrants – Notice of Guaranteed Delivery
PU
Tomorrow is Last Day to Trade SAVAW Warrants on NASDAQ
GL
North American Morning Briefing : Investors Brace -2-
DJ
Cassava Sciences : Corporate Presentation – Second Quarter 2024
PU
Cassava Sciences, Inc. - Redemption Date Announced for Warrants
AQ
Redemption Date Announced for Warrants
GL
Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava
PR
ROSEN, A LONGSTANDING LAW FIRM, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important April 2 Deadline in Securities Class Action - SAVA
PR
Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cassava Sciences, Inc. of Class Action Lawsuit and Upcoming Deadlines - SAVA
PR
Cassava Sciences Announces Completion of Interim Safety Review for Alzheimer's Drug Candidate Simufilam
MT
Cassava Sciences : Corporate Presentation – First Quarter 2024
PU
Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials
GL
Cassava Sciences, Inc. Announces Completion of an Interim Safety Review of Oral Simufilam On-Going Phase 3 Trials
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SAVA Stock
  4. News Cassava Sciences, Inc.